# Real‐World Effectiveness of Sotrovimab in Patients Infected With SARS‐CoV‐2 Omicron Subvariant BA.2 in Western Sydney, Australia

## TL;DR

The study finds that Sotrovimab's real-world effectiveness against SARS-CoV-2 Omicron BA.2 in high-risk patients is comparable to Delta and BA.1 variants in Western Sydney.

## Contribution

This study provides real-world clinical evidence on Sotrovimab's effectiveness against Omicron subvariants, contrasting with in vitro findings.

## Key findings

- Sotrovimab effectiveness against Omicron BA.2 was comparable to Delta and BA.1 in preventing ED visits.
- In vitro findings may not accurately reflect real-world clinical outcomes for Sotrovimab use.

## Abstract

Laboratory‐based findings suggest that Sotrovimab is significantly less effective against emerging CARS‐CoV‐2 variants, however, clinical data is lacking. Here we examined the effectiveness of sotrovimab, in preventing emergency department (ED) presentation and subsequent hospitalization in high‐risk subgroups of patients during the SARS‐CoV‐2 Delta and Omicron waves in Western Sydney, Australia (n = 515). Risk for ED attendance was comparable in Omicron patients, whether BA.1 or BA.2, compared to Delta patients (hazard ratio of 0.97 [0.36–2.64]). These findings highlight the need for caution when using in vitro findings to drive clinical practice, especially when the consequence is to withhold potentially lifesaving treatment.